These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia. Trenkwalder C; Berg D; Rascol O; Eggert K; Ceballos-Baumann A; Corvol JC; Storch A; Zhang L; Azulay JP; Broussolle E; Defebvre L; Geny C; Gostkowski M; Stocchi F; Tranchant C; Derkinderen P; Durif F; Espay AJ; Feigin A; Houeto JL; Schwarz J; Di Paolo T; Feuerbach D; Hockey HU; Jaeger J; Jakab A; Johns D; Linazasoro G; Maruff P; Rozenberg I; Sovago J; Weiss M; Gomez-Mancilla B Mov Disord; 2016 Jul; 31(7):1049-54. PubMed ID: 26990766 [TBL] [Abstract][Full Text] [Related]
8. A Phase Ib Randomized Controlled Study to Evaluate the Effectiveness of a Single-Dose of the NR2B Selective N-Methyl-D-Aspartate Antagonist MK-0657 on Levodopa-Induced Dyskinesias and Motor Symptoms in Patients With Parkinson Disease. Herring WJ; Assaid C; Budd K; Vargo R; Mazenko RS; Lines C; Ellenbogen A; Verhagen Metman L Clin Neuropharmacol; 2017; 40(6):255-260. PubMed ID: 29059133 [TBL] [Abstract][Full Text] [Related]
9. Rasagiline as an adjunct to levodopa in patients with Parkinson's disease and motor fluctuations (LARGO, Lasting effect in Adjunct therapy with Rasagiline Given Once daily, study): a randomised, double-blind, parallel-group trial. Rascol O; Brooks DJ; Melamed E; Oertel W; Poewe W; Stocchi F; Tolosa E; Lancet; 2005 Mar 12-18; 365(9463):947-54. PubMed ID: 15766996 [TBL] [Abstract][Full Text] [Related]
10. Dextromethorphan improves levodopa-induced dyskinesias in Parkinson's disease. Verhagen Metman L; Del Dotto P; Natté R; van den Munckhof P; Chase TN Neurology; 1998 Jul; 51(1):203-6. PubMed ID: 9674803 [TBL] [Abstract][Full Text] [Related]
11. Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson's disease: a dose-finding study. Svenningsson P; Rosenblad C; Af Edholm Arvidsson K; Wictorin K; Keywood C; Shankar B; Lowe DA; Björklund A; Widner H Brain; 2015 Apr; 138(Pt 4):963-73. PubMed ID: 25669730 [TBL] [Abstract][Full Text] [Related]
12. A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease. Tison F; Keywood C; Wakefield M; Durif F; Corvol JC; Eggert K; Lew M; Isaacson S; Bezard E; Poli SM; Goetz CG; Trenkwalder C; Rascol O Mov Disord; 2016 Sep; 31(9):1373-80. PubMed ID: 27214664 [TBL] [Abstract][Full Text] [Related]
13. Tozadenant (SYN115) in patients with Parkinson's disease who have motor fluctuations on levodopa: a phase 2b, double-blind, randomised trial. Hauser RA; Olanow CW; Kieburtz KD; Pourcher E; Docu-Axelerad A; Lew M; Kozyolkin O; Neale A; Resburg C; Meya U; Kenney C; Bandak S Lancet Neurol; 2014 Aug; 13(8):767-76. PubMed ID: 25008546 [TBL] [Abstract][Full Text] [Related]
14. Simvastatin decreases levodopa-induced dyskinesia in monkeys, but not in a randomized, placebo-controlled, multiple cross-over ("n-of-1") exploratory trial of simvastatin against levodopa-induced dyskinesia in Parkinson's disease patients. Tison F; Nègre-Pagès L; Meissner WG; Dupouy S; Li Q; Thiolat ML; Thiollier T; Galitzky M; Ory-Magne F; Milhet A; Marquine L; Spampinato U; Rascol O; Bezard E Parkinsonism Relat Disord; 2013 Apr; 19(4):416-21. PubMed ID: 23283428 [TBL] [Abstract][Full Text] [Related]
15. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL; CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687 [TBL] [Abstract][Full Text] [Related]
16. A trial of dextromethorphan in parkinsonian patients with motor response complications. Verhagen Metman L; Blanchet PJ; van den Munckhof P; Del Dotto P; Natté R; Chase TN Mov Disord; 1998 May; 13(3):414-7. PubMed ID: 9613730 [TBL] [Abstract][Full Text] [Related]
17. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Ferreira JJ; Lees A; Rocha JF; Poewe W; Rascol O; Soares-da-Silva P; Lancet Neurol; 2016 Feb; 15(2):154-165. PubMed ID: 26725544 [TBL] [Abstract][Full Text] [Related]
18. Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson's disease. Warren Olanow C; Kieburtz K; Rascol O; Poewe W; Schapira AH; Emre M; Nissinen H; Leinonen M; Stocchi F; Mov Disord; 2013 Jul; 28(8):1064-71. PubMed ID: 23630119 [TBL] [Abstract][Full Text] [Related]
19. Mavoglurant (AFQ056) in combination with increased levodopa dosages in Parkinson's disease patients. Kumar R; Hauser RA; Mostillo J; Dronamraju N; Graf A; Merschhemke M; Kenney C Int J Neurosci; 2016; 126(1):20-4. PubMed ID: 24007304 [TBL] [Abstract][Full Text] [Related]